Cytisine, a nicotine substitute, more than triples a person's chances of quitting smoking for at least a year, British and Polish researchers say. Lead author Robert West, director of tobacco studies at the Cancer Research UK Health Behavior Research Center at University College London said co-investigator Witold Zatonski, a doctor at the Cancer Center and Institute of Oncology in Warsaw, Poland, had been telling him for years that "there was this pill available in Eastern Europe that he believed was effective and cost next to nothing," to help smokers quit. The drug, sold under the name Tabex to Eastern European countries for more than 40 years, binds with high affinity to the nicotinic acetylcholine receptor, controlling nicotine dependence, Medscape Medical News reported. Although Tabex was withdrawn by some countries when they joined the European Union, it is still available in Poland for about $15 for a treatment course and for about $6 in Russia, Zatonski said. A randomized, controlled trial of more than 740 smokers from Poland, who smoked 10 or more cigarettes a day for 25 days. The study, published in the New England Journal of Medicine, showed significantly more participants receiving cytisine maintained smoking abstinence at six months and one year compared with those receiving a placebo.
GMT 10:31 2018 Tuesday ,13 November
Russian police uproot 70 underground drug labs in past six monthsGMT 16:32 2018 Tuesday ,06 November
Rwanda aims to achieve universal access to clean water by 2024GMT 16:57 2018 Sunday ,04 November
Palestinian women witness higher cure rate of breast cancerGMT 13:11 2018 Tuesday ,30 October
Emergency surgery saves life of touristGMT 10:44 2018 Tuesday ,23 October
Scientists find microplastics in human stool for first timeGMT 09:18 2018 Tuesday ,23 October
US judge upholds Monsanto weedkiller cancer verdict, reduces payoutGMT 14:22 2018 Friday ,19 October
Birth spacing ‘improving health of Omani women’GMT 15:40 2018 Monday ,15 October
Pakistani president launches nationwide anti-measles driveMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor